IQ-AI subsidiary Imaging Biometrics CEO Michael Schmainda shares the latest progress on the group has made on its Phase I brain cancer clinical trial it has sponsored at the Medical College of Wisconsin. Schmainda says the study uses the group's imaging platform which is being used to asses patient's responses, and the group is now enrolling subjects.
IQ-AI subsidiary Imaging Biometrics shares latest progress on Phase I brain cancer study
